108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
Authors:
- M.C. GarassinoMGM.C. Garassino
- J. MazieresJMJ. Mazieres
- M. ReckMRM. Reck
- C. ChouaidCCC. Chouaid
- H. BischoffHBH. Bischoff
- N. ReinmuthNRN. Reinmuth
- L. Cove-SmithLCL. Cove-Smith
- T. MansyTMT. Mansy
- D. CortinovisDCD. Cortinovis
- M.R. MigliorinoMMM.R. Migliorino
- A. DelmonteADA. Delmonte
- J. Garcia SánchezJSJ. Garcia Sánchez
- 2 April 2022
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 33, S81-S82